Most primary care physicians (PCPs) are confident in their abilities to provide cancer survivors with adequate follow-up care, an assurance in the skills of PCPs shared by less than one-fourth of oncologists, who see themselves as better-equipped to care for survivors. Meanwhile, both PCPs and oncologists order significantly more screening than professional guidelines recommend.

As many in the political and public arenas argue that the costs of healthcare are on an unsustainable trajectory, physicians may be reaching their limits as well: the costs of care for oncology “are unsustainable” and require far-reaching changes in treatment and attitudes, among oncologists as well as patients, wrote the authors of a May 25 article in the New England Journal of Medicine (NEJM).

Seegene has entered a partnership with Samsung Medical Center to co-develop molecular diagnostics for cancer.

Pretargeted immunoPET with Immunomedics' TF2 and gallium-68 (68Ga)-labeled peptide is a sensitive imaging method for colon cancer and is more specific than FDG PET, according to results presented at the annual meeting of the American Association for Cancer Research (AACR) this week in Orlando, Fla.